liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis
Univ Freiburg, Germany.
Univ Hosp Frankfurt, Germany.
Univ Freiburg, Germany.
Univ Mannheim, Germany.
Show others and affiliations
2021 (English)In: European Neuropsychopharmacology, ISSN 0924-977X, E-ISSN 1873-7862, Vol. 44, p. 105-120Article in journal (Refereed) Published
Abstract [en]

There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy. Crown Copyright (C) 2021 Published by Elsevier B.V. All rights reserved.

Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 44, p. 105-120
Keywords [en]
Serotonin transporter gene; Therapygenetics; Treatment response; Therapy outcome; CBT; Panic disorder
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:liu:diva-174376DOI: 10.1016/j.euroneuro.2021.01.004ISI: 000620608600009PubMedID: 33483252Scopus ID: 2-s2.0-85099635301OAI: oai:DiVA.org:liu-174376DiVA, id: diva2:1538754
Note

Funding Agencies|German Research Foundation (DFG)German Research Foundation (DFG) [44541416 -TRR 58, SFB 1193 Z03]; German Ministry of Research and Education (BMBF, PROTECT-AD)Federal Ministry of Education & Research (BMBF) [01EE1402F]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0901874]; German Federal Ministry of Education and Research (BMBF) as part of the larger BMBF Psychotherapy Research Funding Initiative Improving the Treatment of Panic Disorder [01GV0614]

Available from: 2021-03-21 Created: 2021-03-21 Last updated: 2022-05-23Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Andersson, Gerhard

Search in DiVA

By author/editor
Andersson, Gerhard
By organisation
PsychologyFaculty of Arts and Sciences
In the same journal
European Neuropsychopharmacology
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf